Am. J. Respir. Crit. Care Med.,
Volume 159, Number 6, June 1999, 1925-1932
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
P. J. Troy and A. B. Waxman Review: Portopulmonary hypertension: challenges in diagnosis and management Therapeutic Advances in Gastroenterology, September 1, 2009; 2(5): 281 - 286. [Abstract] [PDF] |
||||
![]() |
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S55 - S66. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF] |
||||
![]() |
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF] |
||||
![]() |
H. Olschewski Inhaled iloprost for the treatment of pulmonary hypertension Eur. Respir. Rev., March 1, 2009; 18(111): 29 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Davies and N. W. Morrell Molecular Mechanisms of Pulmonary Arterial Hypertension: Role of Mutations in the Bone Morphogenetic Protein Type II Receptor Chest, December 1, 2008; 134(6): 1271 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mukhopadhyay, J. Lee, and P. B. Sehgal Depletion of the ATPase NSF from Golgi membranes with hypo-S-nitrosylation of vasorelevant proteins in endothelial cells exposed to monocrotaline pyrrole Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1943 - H1955. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Schermuly, J-P. Stasch, S. S. Pullamsetti, R. Middendorff, D. Muller, K-D. Schluter, A. Dingendorf, S. Hackemack, E. Kolosionek, C. Kaulen, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Eur. Respir. J., October 1, 2008; 32(4): 881 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Rai, C. D. Cool, J. A. C. King, T. Stevens, N. Burns, R. A. Winn, M. Kasper, and N. F. Voelkel The Cancer Paradigm of Severe Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 558 - 564. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 691 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Benza, B. K. Rayburn, J. A. Tallaj, S. V. Pamboukian, and R. C. Bourge Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension: Long-term Efficacy and Combination With Bosentan Chest, July 1, 2008; 134(1): 139 - 145. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Amabile, C. Heiss, W. M. Real, P. Minasi, D. McGlothlin, E. J. Rame, W. Grossman, T. De Marco, and Y. Yeghiazarians Circulating Endothelial Microparticle Levels Predict Hemodynamic Severity of Pulmonary Hypertension Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1268 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Fredenburgh, O. D. Liang, A. A. Macias, T. R. Polte, X. Liu, D. F. Riascos, S. W. Chung, S. L. Schissel, D. E. Ingber, S. A. Mitsialis, et al. Absence of Cyclooxygenase-2 Exacerbates Hypoxia-Induced Pulmonary Hypertension and Enhances Contractility of Vascular Smooth Muscle Cells Circulation, April 22, 2008; 117(16): 2114 - 2122. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. SWANSON and M. J. KROWKA Screen for portopulmonary hypertension, especially in liver transplant candidates Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 121 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Hamidi, S. Prabhakar, and S. I. Said Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion Eur. Respir. J., January 1, 2008; 31(1): 135 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sakao, L. Taraseviciene-Stewart, C. D. Cool, Y. Tada, Y. Kasahara, K. Kurosu, N. Tanabe, Y. Takiguchi, K. Tatsumi, T. Kuriyama, et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells FASEB J, November 1, 2007; 21(13): 3640 - 3652. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kuwano, A. Hashino, T. Asaki, T. Hamamoto, T. Yamada, K. Okubo, and K. Kuwabara 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1181 - 1188. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al. Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats Hypertension, September 1, 2007; 50(3): 531 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jain, H. Ventura, and B. deBoisblanc Pathophysiology of Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 104 - 109. [Abstract] [PDF] |
||||
![]() |
S. Takaoka, J. L. Faul, and R. Doyle Current Therapies for Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148. [Abstract] [PDF] |
||||
![]() |
S. D. Nathan, P. W. Noble, and R. M. Tuder Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Nana-Sinkam, J. D. Lee, S. Sotto-Santiago, R. S. Stearman, R. L. Keith, Q. Choudhury, C. Cool, J. Parr, M. D. Moore, T. M. Bull, et al. Prostacyclin Prevents Pulmonary Endothelial Cell Apoptosis Induced by Cigarette Smoke Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 676 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Steiner, I. R. Preston, J. R. Klinger, G. J. Criner, A. B. Waxman, H. W. Farber, and N. S. Hill Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest, November 1, 2006; 130(5): 1471 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Eur. Respir. J., October 1, 2006; 28(4): 683 - 686. [Full Text] [PDF] |
||||
![]() |
L. Taraseviciene-Stewart, R. Scerbavicius, K.-H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper, and N. F. Voelkel Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L668 - L676. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Said Mediators and modulators of pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Peacock, G. Simonneau, and L. Rubin Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension Proceedings of the ATS, September 1, 2006; 3(7): 608 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Lovgren, L. A. Jania, J. M. Hartney, K. K. Parsons, L. P. Audoly, G. A. FitzGerald, S. L. Tilley, and B. H. Koller COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L144 - L156. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guignabert, M. Izikki, L. I. Tu, Z. Li, P. Zadigue, A.-M. Barlier-Mur, N. Hanoun, D. Rodman, M. Hamon, S. Adnot, et al. Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension Circ. Res., May 26, 2006; 98(10): 1323 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Eddahibi, C. Guignabert, A.-M. Barlier-Mur, L. Dewachter, E. Fadel, P. Dartevelle, M. Humbert, G. Simonneau, N. Hanoun, F. Saurini, et al. Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension: Critical Role for Serotonin-Induced Smooth Muscle Hyperplasia Circulation, April 18, 2006; 113(15): 1857 - 1864. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hoeper and L. J. Rubin Update in pulmonary hypertension 2005. Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 499 - 505. [Full Text] [PDF] |
||||
![]() |
T. Stevens Molecular and Cellular Determinants of Lung Endothelial Cell Heterogeneity Chest, December 1, 2005; 128(6_suppl): 558S - 564S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Cool, S. D. Groshong, J. Oakey, and N. F. Voelkel Pulmonary Hypertension: Cellular and Molecular Mechanisms Chest, December 1, 2005; 128(6_suppl): 565S - 571S. [Full Text] [PDF] |
||||
![]() |
C.-F. Lam, T. E. Peterson, A. J. Croatt, K. A. Nath, and Z. S. Katusic Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2334 - H2341. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zaiman, I. Fijalkowska, P. M. Hassoun, and R. M. Tuder One Hundred Years of Research in the Pathogenesis of Pulmonary Hypertension Am. J. Respir. Cell Mol. Biol., November 1, 2005; 33(5): 425 - 431. [Full Text] [PDF] |
||||
![]() |
L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Fike, Y. Zhang, and M. R. Kaplowitz Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets J Appl Physiol, August 1, 2005; 99(2): 670 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Rashid and D Ivy Severe paediatric pulmonary hypertension: new management strategies Arch. Dis. Child., January 1, 2005; 90(1): 92 - 98. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Phillips, L. Long, M. R. Wilkins, and N. W. Morrell cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling Am J Physiol Lung Cell Mol Physiol, January 1, 2005; 288(1): L103 - L115. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic Pulmonary-Hepatic vascular Disorders (PHD) Eur. Respir. J., November 1, 2004; 24(5): 861 - 880. [Full Text] [PDF] |
||||
![]() |
H. W. Farber and J. Loscalzo Pulmonary Arterial Hypertension N. Engl. J. Med., October 14, 2004; 351(16): 1655 - 1665. [Full Text] [PDF] |
||||
![]() |
M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF] |
||||
![]() |
M.M. Hoeper and A.T. Dinh-Xuan Combination therapy for pulmonary arterial hypertension: still more questions than answers Eur. Respir. J., September 1, 2004; 24(3): 339 - 340. [Full Text] [PDF] |
||||
![]() |
M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galie, A. Boonstra, L.J. Rubin, E.M. Horn, A. Manes, and G. Simonneau Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur. Respir. J., September 1, 2004; 24(3): 353 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Langer, R. Schramm, M. Bauer, D. Tscholl, T. Kunihara, and H.-J. Schafers Cytokine Response to Pulmonary Thromboendarterectomy Chest, July 1, 2004; 126(1): 135 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Newman, B. L. Fanburg, S. L. Archer, D. B. Badesch, R. J. Barst, J. G.N. Garcia, P. N. Kao, J. A. Knowles, J. E. Loyd, M. D. McGoon, et al. Pulmonary Arterial Hypertension: Future Directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases Workshop Circulation, June 22, 2004; 109(24): 2947 - 2952. [Full Text] [PDF] |
||||
![]() |
M. Humbert, N. W. Morrell, S. L. Archer, K. R. Stenmark, M. R. MacLean, I. M. Lang, B. W. Christman, E. K. Weir, O. Eickelberg, N. F. Voelkel, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 13S - 24S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst Prostanoid therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Rubin and N. Galie Pulmonary arterial hypertension: a look to the future J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 89S - 90S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. El-Haroun, D. Bradbury, A. Clayton, and A. J. Knox Interleukin-1{beta}, Transforming Growth Factor-{beta}1, and Bradykinin Attenuate Cyclic AMP Production by Human Pulmonary Artery Smooth Muscle Cells in Response to Prostacyclin Analogues and Prostaglandin E2 by Cyclooxygenase-2 Induction and Downregulation of Adenylyl Cyclase Isoforms 1, 2, and 4 Circ. Res., February 20, 2004; 94(3): 353 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 227 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Budhiraja, R. M. Tuder, and P. M. Hassoun Endothelial Dysfunction in Pulmonary Hypertension Circulation, January 20, 2004; 109(2): 159 - 165. [Full Text] [PDF] |
||||
![]() |
H. K. Takahashi, H. Iwagaki, R. Tamura, D. Xue, M. Sano, S. Mori, T. Yoshino, N. Tanaka, and M. Nishibori Unique Regulation Profile of Prostaglandin E1 on Adhesion Molecule Expression and Cytokine Production in Human Peripheral Blood Mononuclear Cells J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1188 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Cooke A Novel Mechanism for Pulmonary Arterial Hypertension? Circulation, September 23, 2003; 108(12): 1420 - 1421. [Full Text] [PDF] |
||||
![]() |
P. N. Kao and J. L. Faul Emerging therapies for pulmonary hypertension: Striving for efficacy and safety J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2126 - 2129. [Full Text] [PDF] |
||||
![]() |
S. Ameshima, H. Golpon, C. D. Cool, D. Chan, R. W. Vandivier, S. J. Gardai, M. Wick, R. A. Nemenoff, M. W. Geraci, and N. F. Voelkel Peroxisome Proliferator-Activated Receptor Gamma (PPAR{gamma}) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth Circ. Res., May 30, 2003; 92(10): 1162 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Barbera, V.I. Peinado, and S. Santos Pulmonary hypertension in chronic obstructive pulmonary disease Eur. Respir. J., May 1, 2003; 21(5): 892 - 905. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hoshikawa, P. Nana-Sinkam, M. D. Moore, S. Sotto-Santiago, T. Phang, R. L. Keith, K. G. Morris, T. Kondo, R. M. Tuder, N. F. Voelkel, et al. Hypoxia induces different genes in the lungs of rats compared with mice Physiol Genomics, February 6, 2003; 12(3): 209 - 219. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Budhiraja and P. M. Hassoun Portopulmonary Hypertension: A Tale of Two Circulations Chest, February 1, 2003; 123(2): 562 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Blumberg, K. Wolf, M. Arzt, C. Lorenz, G. A. J. Riegger, and M. Pfeifer Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs J Appl Physiol, February 1, 2003; 94(2): 446 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Fike, M. R. Kaplowitz, and S. L. Pfister Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L316 - L323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Eddahibi, N. Morrell, M-P. d'Ortho, R. Naeije, and S. Adnot Pathobiology of pulmonary arterial hypertension Eur. Respir. J., December 1, 2002; 20(6): 1559 - 1572. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Rubin Therapy of Pulmonary Hypertension: The Evolution from Vasodilators to Antiproliferative Agents Am. J. Respir. Crit. Care Med., November 15, 2002; 166(10): 1308 - 1309. [Full Text] [PDF] |
||||
![]() |
C. Yokoyama, T. Yabuki, M. Shimonishi, M. Wada, T. Hatae, S. Ohkawara, J. Takeda, T. Kinoshita, M. Okabe, and T. Tanabe Prostacyclin-Deficient Mice Develop Ischemic Renal Disorders, Including Nephrosclerosis and Renal Infarction Circulation, October 29, 2002; 106(18): 2397 - 2403. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Galie, A. Manes, and A. Branzi The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Eur. Respir. J., October 1, 2002; 20(4): 1037 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Coe, S. J. Haleen, K. M. Welch, Y.-A. Liu, and F. Coceani The Endothelin A Receptor Antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) Reverse the Hypoxic Pulmonary Vasoconstriction in the Perinatal Lamb J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 672 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C Blumberg, C. Lorenz, K. Wolf, P. Sandner, G. A.J Riegger, and M. Pfeifer Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension Cardiovasc Res, July 1, 2002; 55(1): 171 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Swanson and M. J. Krowka Arterial Oxygenation Associated With Portopulmonary Hypertension* Chest, June 1, 2002; 121(6): 1869 - 1875. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Galie, M. Humbert, J.-L. Vachiery, C. Vizza, M. Kneussl, A. Manes, O. Sitbon, A. Torbicki, M. Delcroix, R. Naeije, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1496 - 1502. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF] |
||||
![]() |
M. Beghetti, G. Reber, P. de Moerloose, L. Vadas, A. Chiappe, I. Spahr-Schopfer, and P.C. Rimensberger Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation Eur. Respir. J., March 1, 2002; 19(3): 518 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. DORFMULLER, V. ZARKA, I. DURAND-GASSELIN, G. MONTI, K. BALABANIAN, G. GARCIA, F. CAPRON, A. COULOMB-LHERMINE, A. MARFAING-KOKA, G. SIMONNEAU, et al. Chemokine RANTES in Severe Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., February 15, 2002; 165(4): 534 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tuder and A. L. Zaiman Prostacyclin Analogs as the Brakes for Pulmonary Artery Smooth Muscle Cell Proliferation . Is It Sufficient to Treat Severe Pulmonary Hypertension? Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 171 - 174. [Full Text] [PDF] |
||||
![]() |
L. H. Clapp, P. Finney, S. Turcato, S. Tran, L. J. Rubin, and A. Tinker Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 194 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Keith, Y. E. Miller, Y. Hoshikawa, M. D. Moore, T. L. Gesell, B. Gao, A. M. Malkinson, H. A. Golpon, R. A. Nemenoff, and M. W. Geraci Manipulation of Pulmonary Prostacyclin Synthase Expression Prevents Murine Lung Cancer Cancer Res., February 1, 2002; 62(3): 734 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Roberts, J. J. Lepore, A. Maroo, M. J. Semigran, and L. C. Ginns Oxygen Therapy Improves Cardiac Index and Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension Chest, November 1, 2001; 120(5): 1547 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Fike, M. R. Kaplowitz, and M. Bousamra II eNOS and prostanoid enzymes in lungs of newborn piglets with chronic aortopulmonary shunts Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L475 - L482. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. F. BERGER, R. GEIGER, J. HESS, A. J. J. C. BOGERS, and W. J. MOOI Altered Arterial Expression Patterns of Inducible and Endothelial Nitric Oxide Synthase in Pulmonary Plexogenic Arteriopathy Caused by Congenital Heart Disease Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1493 - 1499. [Abstract] [Full Text] |
||||
![]() |
M. W. Geraci, M. Moore, T. Gesell, M. E. Yeager, L. Alger, H. Golpon, B. Gao, J. E. Loyd, R. M. Tuder, and N. F. Voelkel Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension : A Gene Microarray Analysis Circ. Res., March 30, 2001; 88(6): 555 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wharton, N. Davie, P. D. Upton, M. H. Yacoub, J. M. Polak, and N. W. Morrell Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells Circulation, December 19, 2000; 102(25): 3130 - 3136. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagaya, C. Yokoyama, S. Kyotani, M. Shimonishi, R. Morishita, M. Uematsu, T. Nishikimi, N. Nakanishi, T. Ogihara, M. Yamagishi, et al. Gene Transfer of Human Prostacyclin Synthase Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats Circulation, October 17, 2000; 102(16): 2005 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. YI, H. KIM, H. AHN, J. STROTHER, T. MORRIS, E. MASLIAH, L. A. HANSEN, K. PARK, and P. J. FRIEDMAN Distribution of Obstructive Intimal Lesions and Their Cellular Phenotypes in Chronic Pulmonary Hypertension . A Morphometric and Immunohistochemical Study Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1577 - 1586. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hampl and J. Herget Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension Physiol Rev, October 1, 2000; 80(4): 1337 - 1372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J KROWKA Hepatopulmonary syndromes Gut, January 1, 2000; 46(1): 1 - 4. [Full Text] [PDF] |
||||
![]() |
C. D. Cool, J. S. Stewart, P. Werahera, G. J. Miller, R. L. Williams, N. F. Voelkel, and R. M. Tuder Three-Dimensional Reconstruction of Pulmonary Arteries in Plexiform Pulmonary Hypertension Using Cell-Specific Markers : Evidence for a Dynamic and Heterogeneous Process of PulmonaryEndothelial Cell Growth Am. J. Pathol., August 1, 1999; 155(2): 411 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Langleben, R. J. Barst, D. Badesch, B. M. Groves, V. F. Tapson, S. Murali, R. C. Bourge, N. Ettinger, E. Shalit, L. M. Clayton, et al. Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension Circulation, June 29, 1999; 99(25): 3266 - 3271. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Ivy, M. Yanagisawa, C. E. Gariepy, S. A. Gebb, K. L. Colvin, and I. F. McMurtry Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats Am J Physiol Lung Cell Mol Physiol, April 1, 2002; 282(4): L703 - L712. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |